ATX.AU Amplia Therapeutics Ltd

Healthcare Biotechnology Australian Securities Exchange
0.0840 AUD
Close of Oct 30, 2026
0.0760 0.2750
Market cap
AUD 43.1M
P/E
-
P/B
1.09x
ROE
-19.5%
Dividend yield
-
Fundamental score
2.0/5

Ratios use the latest price and the fiscal year ending Mar 2026.

Is ATX.AU undervalued?

Graham number

The Graham number of Amplia Therapeutics Ltd cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Amplia Therapeutics Ltd fundamental analysis

9 of 21 checks passed

ROE 0/2

Low return on equity (-19.5%), below 10%.

ROA 1/1

Return on assets (-18.6%) is above the industry median (-51.4%).

Profit Consistency 0/2

Not profitable for at least 3 consecutive years.

Earnings Growth 5Y 1/1

Earnings per share grew over the past 5 years.

Earnings Acceleration 0/1

Not enough positive earnings history to compare last year's growth with the 5-year average.

Earnings Growth vs Industry 1/1

Last year's EPS growth (23.3%) is above the industry median (-5.3%).

Revenue Growth 0/2

Revenue did not grow over the past 3 years or is not reported.

Short-term Liquidity 1/1

Current assets cover short-term liabilities.

Long-term Liabilities 1/1

Current assets cover long-term liabilities.

Debt to Equity 2/2

Low debt to equity (0.9%), 40% or less.

Debt Trend 1/1

Debt to equity has not risen over the past 5 years.

Cash Runway 2/2

Cash covers 3.2 years of the current cash burn.

PE vs Market 0/1

PE is negative or not available.

PE vs Industry 0/1

PE is negative or not available.

PBV 1/1

Price to book (1.1x) is below the industry median (4.4x).

Graham Number 0/1

Graham number needs positive earnings and book value.

PEG 0/1

PEG needs positive PE and positive 5-year earnings growth.

Dividend Yield 0/2

No dividend paid in the last reported year.

Dividend Stability 0/2

Dividends were not paid steadily for the past 5 years.

Dividend Growth 0/1

Dividends paid did not grow over the past 5 years.

Payout Ratio 0/1

No dividend, or no profit to pay it from.

Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score

Amplia Therapeutics Ltd stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Amplia Therapeutics Ltd

Amplia Therapeutics Limited, a clinical-stage drug development company, engages in the development of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia. Its product pipeline comprises Narmafotinib (AMP945), an inhibitor of FAK, which is in phase 2b clinical trial for pancreatic cancer; and treatment of ovarian cancer. It also develops AMP886 for application in oncology and chronic fibrosis indications. The company was formerly known as Innate Immuno…

Full company profile